TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: peak post-extubation Edi levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total energy intake vs total energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: behavioral stress norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavioral stress BP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of early death due to comorbidity
Endpoint domain: Mortality/survival
Primary endpoint: 4-hour systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean pulmonary artery attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subsegmental attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of death or rehospitalization for myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Average time to a main event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of NSE, SP and CGRP in local blister fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentration of 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients in need of ephedrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median rate of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: migraine intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of triptans used
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: reductions in drug cravings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer visits to healthcare providers
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Nocturia Impact Diary
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to achieve therapeutic INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving therapeutic INR by day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of INR assessments performed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: annualized incidence rates of upper GI ulcer complications combined with symptomatic ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: intrapartum-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: use of bag-and-mask ventilation for babies with low Apgar score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total work across all sets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T(PEAK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: k(e0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to eye opening on verbal command
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to discharge from the recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior Kmax-3 mm reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior Kmax-8 mm reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for surgical tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Precision in surgical tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Camera utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: area of pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: average gray value of pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Readmissions at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: median number of incontinence episodes/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom of any atrial tachyarrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: annual monetary costs of AD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of mild pancreatitis (PEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in body fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EPC colony number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: wm FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: plasma copeptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cognitive performance improvement (RBANS Total scale score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: validated point prevalence abstinence at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: validated point prevalence abstinence at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semaglutide exposure (AUC0‐24h and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Preference for DTE therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: train-of-four ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 50% improvement in BASDAI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial hemorrhage (ICH) events
Endpoint domain: Mortality/survival
Primary endpoint: Rate of death or disability at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Composite rate of myocardial infarction, stroke, and death up to 1 year
Endpoint domain: Mortality/survival
Primary endpoint: vascular response to acetylcholine iontophoresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of clinically defined influenza infection
Endpoint domain: Adverse events/effects
Primary endpoint: Time free from clinically defined influenza infection
Endpoint domain: Adverse events/effects
Primary endpoint: Device acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: superiority in compression therapy for venous ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative dose requirements of cisatracurium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Functional connectivity between VTA and food motivation brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: higher-risk major disability at 90-day assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: RM score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthcare system costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in symptom severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of facial ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: Good functional outcome (mRS 0-2)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: In-hospital seizures
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral Blood Flow Augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: n‐3 PUFA proportions in plasma phospholipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: n‐6 PUFA proportions in plasma phospholipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in subgingival organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: annual mean per participant costs for prescription medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: annual mean per participant costs for hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: annual mean per participant total costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sensitivity for detection of perfusion defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity for detection of perfusion defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healing of duodenal ulcer (DU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects related to medication
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of rapid tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AI adherence at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement for analgesic medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement for anti-emetic medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in colony forming units
Endpoint domain: Adverse events/effects
Primary endpoint: Normalization of homocysteinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Occupational exposure to desflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occupational exposure to isoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ferritin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion rates for 9vHPV vaccine types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of admission rectal temperature <36 °C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: admission rectal temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total laboratory costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Thrombus treatment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of PACU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean levels of PDGF-BB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Needle visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement of Metabolic Syndrome (MetS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in systolic blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Loss of fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in documentation errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI comparison between cases and controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total body mass reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth and body fatness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limited exercise time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right ventricular systolic and diastolic pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV end diastolic volume (EDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to complete the examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) at femur neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole body Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of protective efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Urine calcium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: visuospatial working memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in stool consistencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in stool frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of Major Depressive Disorder (MDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Staple line leak incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in cumulative Gd+ lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Participants remaining free of Gd+ lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in cumulative new T2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Participants remaining free of new T2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mortality of patients with severe sepsis
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of severe sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of patients who avoided transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: average units of blood transfused
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Nonprotein-bound iron levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrical brain activity (ECBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End stage renal disease evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: sufficient CC depth ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waking sAA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported sleep improvement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: fertility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 15-year actuarial locoregional recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: rate of severe acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: rate of severe late RT complications
Endpoint domain: Adverse events/effects
Primary endpoint: muscle damage (plasma CPK levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine Efficacy (VE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SIDI-F score indicating presence of HSDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Halimeter scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organoleptic scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modelled IDV clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IDV peak and trough concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in fall-related injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to disease relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of joints and enthesis involved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Glucose Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline on the AAQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acceptability of the aquatic environment for exercise training
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cumulative survival rate at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: low-density lipoprotein cholesterol level <100mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hemoglobin A(1c) <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Immunogenicity of the inactivated influenza vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety in terms of local and systemic side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Visual field deficit progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual medical care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in involvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement in autonomy-support
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Food availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Homeostasis Model Assessment (HOMA) indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: aPAI‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate screening behavior at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Appropriate screening intent following the provider visit
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes in the length and width of erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Accelerated recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implantation-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Average time of implantation into the ileocecum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Development of significant insulin antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood glucose levels < 70 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LAA sensitivity of leukemic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Insurance payments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Net Income
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Association of SNP rs1898671 with asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TXB(2) release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: general cognitive ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C decline after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglycerides decline after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL-C increase after 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: self-sufficiency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adverse cardiac events during 6-months follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Impaired subendocardial perfusion reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: major molecular response (MMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete cytogenetic response (CCyR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological robustness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance with CBC Hgb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes